Towards Healthcare Research & Consulting

DNA Testing Market Size, Share, Forecast (2026-2035), Clinical Genetic, Oncology, Prenatal, Consumer, Forensic and Paternity DNA Tests

The DNA testing market is estimated at USD 27.01 billion in 2026 and is projected to reach USD 62.66 billion by 2035, expanding at a CAGR of 9.80% from 2026 to 2035. The market was valued at USD 24.60 billion in 2025, which is the base year. The market comprises tests that analyze human DNA, including clinical diagnostic and hereditary disease testing, oncology genetic testing, prenatal and newborn testing, and direct-to-consumer ancestry. It also involves health tests, forensic DNA testing, and paternity and relationship testing, using PCR, next-generation sequencing, microarray and other technologies, and offered by hospitals and clinics, diagnostic laboratories, forensic laboratories and consumer testing companies. Clinical & Hereditary Disease Testing accounted for the largest test type share of 30.00% in 2025, because exome, panel and carrier tests are widely used in care.

Last updated 17 November 2026   |   Primary source: Towards Healthcare   |   Report: 7201   |   Derived values are labelled
USD 27.01 Bn
Revenue, 2026
USD 62.66 Bn
Forecast, 2035
9.80%
CAGR, 2026-2035
Global
Report Coverage

Key Takeaways

DNA Testing Market Snapshot, Comparison and Top Companies

Market Size & Growth Outlook

  • Market size in 2025: USD 24.60 billion
  • Estimated market size in 2026: USD 27.01 billion
  • Projected market size by 2035: USD 62.66 billion
  • CAGR (2026-2035): 9.80%

Regional Market Spotlight

  • North America led the market with a 44.00% share in 2025.
  • Europe accounted for 27.00% of the market in 2025.
  • Asia Pacific held a 22.00% share in 2025 and is projected to be the fastest-growing region, at a CAGR of 10.90% from 2026 to 2035.

Segmental Spotlight

  • By test type, Clinical & Hereditary Disease Testing accounted for 30.00% of revenue in 2025.
  • By technology, Next-Generation Sequencing held a 42.00% share in 2025.
  • Diagnostic Laboratories captured 46.00% revenue in the end-user segment in 2025.

The market is projected to grow from USD 24.60 billion in 2025 to USD 62.66 billion by 2035 because DNA testing is used across healthcare, family planning, forensics and consumer interest, and falling sequencing costs widen access. The market growth is being driven by falling sequencing costs, precision medicine, prenatal testing and forensic use. The market is expected to reach USD 39.26 billion by 2030 and sustain a CAGR of 9.80% from 2026 to 2035. DNA testing relies on next-generation sequencing and genomics to deliver precision medicine.

DNA Testing Market Size is USD 27.01 Billion in 2026.

Analyst View: We built the estimate from DNA test volumes and average prices by test type and region, cross-checked against genetic testing revenues of leading laboratories and consumer firms. Our value sits above published comparable estimates because it includes clinical, consumer and forensic tests.

  • The costs of DNA sequencing are decreasing, which improves the affordability of genetic testing.
  • Genomic newborn screening is gaining traction for timely detection of inherited genetic disorders.
  • The demand for hereditary cancer testing is increasing, which supports the identification of individuals with genetic cancer risks.
  • There are growing concerns regarding consumer DNA data privacy, which fuels the demand for stronger genetic data protection and security measures.
  • Forensic genetic genealogy is expanding the use of DNA testing in criminal investigations and unidentified-person identification.
  • The significance of pharmacogenomics is increasing in personalized medicine as it helps healthcare providers select treatments based on the genetic profiles of the patients.

Drivers, Restraints and Opportunities

Market Drivers - Impact & CAGR Contribution (2026-2035)

Driver Impact ≈ CAGR Contribution Time Horizon Key Regions
Sequencing costs fall High +3.83 pp Short to long term Global, strongest in North America
Precision medicine grows Medium +3.23 pp Medium to long term Global, fastest uptake in Asia Pacific
Prenatal testing expands Medium +2.75 pp Short to medium term Global
Consumer interest continues Low +2.15 pp Long term Developed and emerging markets

Note: Contributions are indicative estimates of each factor's effect on annual growth.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Taken together, these drivers add about 11.96 percentage points to the annual growth of the DNA testing market, with sequencing costs falling having the largest effect. Their influence is strongest in North America, while uptake grows fastest in Asia Pacific.

Market Restraints - Impact & Negative CAGR Contribution (2026-2035)

Restraint Impact ≈ Negative CAGR Contribution Time Horizon Key Regions
Privacy concerns High -0.97 pp Short to medium term Global
Reimbursement gaps High -0.71 pp Medium term Price-sensitive and emerging markets
Genetic counsellor shortages Medium -0.47 pp Short term North America and other mature markets

Note: Contributions are indicative estimates of each factor's effect on annual growth.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

These restraints are expected to reduce annual growth of the DNA testing market by about 2.16 percentage points, led by privacy concerns. Their effect eases over the forecast period as suppliers, buyers, and regulators adapt, leaving a net CAGR of 9.80% from 2026 to 2035.

Opportunity

Expanding genomic newborn screening programs create opportunities for DNA testing providers. Pharmacogenomics is being increasingly adopted, which fuels the demand for genetic testing to guide personalized drug selection and dosage decisions. The demand for genetic testing is Asia is increasing, which presents market growth potential. Growing adoption of forensic genetic genealogy creates opportunities for DNA testing technologies in criminal investigation. The interest in whole-genome sequencing is increasing, which drives the demand for comprehensive genetic analysis.

Market Segmentation: 2025 Share and Value

DNA Testing Market by Test Type 2025 Share

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.

Clinical & Hereditary Disease Testing held 30.00% of revenue in 2025 and is projected to expand at a CAGR of 9.09% during the forecast period. Clinical and hereditary disease testing leads because exome, panel, and carrier tests are widely used in care. This segment is expected to grow slower than the overall market over the forecast period.

Oncology Genetic Testing grows fastest, with tumor profiling and hereditary cancer tests. This segment is expected to grow faster than the market between 2026 and 2035.

Prenatal & Newborn Testing includes NIPT and newborn screening. The prenatal & newborn testing segment is expected to grow slower than the overall market over the forecast period.

Direct-to-Consumer Testing covers ancestry and wellness. The direct-to-consumer testing segment is expected to grow slower than the overall market from 2026 to 2035.

Forensic & Paternity Testing serve justice and family needs. This segment is expected to grow at a slower rate than the market over the forecast period.

Segment Outlook: Clinical & Hereditary Disease Testing remains the largest test type segment through 2035, holding about 28.14% of the market in 2035, while Oncology Genetic Testing records the highest CAGR of 10.99% from 2026 to 2035. Direct-to-Consumer Testing holds the smallest share today and serves more specialised needs within the DNA testing market.

DNA Testing Market by Technology 2025 Share

DNA Testing Market Share, By Technology, 2025 (%)

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.

Next-Generation Sequencing accounted for 42.00% of the market in 2025 and is projected to expand at a CAGR of 10.48% from 2026 to 2035. Next-generation sequencing leads and grows fastest because costs keep falling. This segment is expected to grow faster than the market throughout the forecast period.

PCR serves targeted and forensic tests. The PCR segment is expected to grow at a slower pace than the market between 2026 and 2035.

Microarray serves consumer and cytogenetic tests. This segment is expected to grow slower than the overall market over the forecast period.

Others methods include Sanger and capillary electrophoresis. The others segment is expected to grow slower than the overall market over the forecast period.

Segment Outlook: Next-Generation Sequencing remains the largest technology segment through 2035, holding about 44.69% of the market in 2035, and also records the highest CAGR of 10.48% from 2026 to 2035, strengthening its lead in the DNA testing market.

DNA Testing Market by End User 2025 Share

DNA Testing Market, By End User in 2025.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Precedence Research database, and Precedence Research analysts.

Diagnostic Laboratories accounted for a 46.00% share in 2025 and is projected to grow at a CAGR of 9.31% from 2026 to 2035. Diagnostic laboratories lead because they run most clinical DNA tests. This segment is expected to grow slower than the overall market over the forecast period.

Hospitals & Clinics order and run tests. The hospitals & clinics segment is expected to grow faster than the overall market between 2026 and 2035.

Forensic Laboratories process crime and identity samples. This segment is expected to grow broadly in line with the overall market over the forecast period.

Consumers buy kits online, this segment is expected to grow broadly in line with the overall market between 2026 and 2035.

Segment Outlook: Diagnostic Laboratories remains the largest end user segment through 2035, holding about 44.00% of the market in 2035, while Hospitals & Clinics records the highest CAGR of 10.71% from 2026 to 2035. Forensic Laboratories holds the smallest share today and serves more specialised needs within the DNA testing market.

Analyst View: Segment shares were allocated from demand, product portfolios, and pricing in each category. Clinical & Hereditary Disease Testing, Next-Generation Sequencing and Diagnostic Laboratories lead their categories because they meet the core needs of today's buyers. We expect Oncology Genetic Testing and Hospitals & Clinics to gain share as newer technologies, users and applications grow faster.

Regional Analysis

DNA Testing Market by Region 2025 Share

DNA Testing Market Shares for North America, Europe, Asia Pacific, Latin America and Middle East and Africa, 2025 (%).

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.

North America captured 44.00% of the market in 2025 and is projected to expand at a CAGR of 9.30% from 2026 to 2035. North America leads because of broad clinical genetic testing, large consumer DNA databases, and reimbursement. North America is expected to grow slower than the overall market over the forecast period.

Europe has national genomic medicine services. Europe is expected to grow broadly in line with the market throughout the forecast period.

Asia Pacific grows fastest with large NIPT volumes in China and expanding genomics in India and Japan. Asia Pacific is expected to grow faster than the overall market over the forecast period.

Latin America is expanding prenatal and paternity tests. This region is expected to grow broadly in line with the market between 2026 and 2035.

Middle East & Africa run national genome programs. This region is expected to grow broadly in line with the overall market over the forecast period.

Analyst View: Regional shares were built from demand, installed base, spending, and supplier presence in each region. North America leads because of its mature demand base and strong suppliers. We assign Asia Pacific the highest growth premium because investment, adoption, and capacity are expanding fastest there.

Competitive Landscape

DNA Testing Market Companies are Natera, Labcorp, Illumina, Quest Diagnostics, Thermo Fisher Scientific, BGI Genomics, Ancestry, Exact Sciences, Myriad Genetics

Top 10 Companies in the DNA Testing Market, 2025

Rank Company Name 2025 Share (%) Key Products / Business Headquarters
1 Natera 24.39% Panorama NIPT, Signatera and Horizon carrier tests United States
2 Labcorp 24.39% Genetic and Invitae testing United States
3 Illumina 24.39% Sequencing systems and assays United States
4 Quest Diagnostics 20.33% Clinical genetic testing United States
5 Thermo Fisher Scientific 20.33% PCR, sequencing and forensic DNA kits United States
6 BGI Genomics 16.26% NIPT and genetic testing China
7 Ancestry 16.26% AncestryDNA consumer tests United States
8 Exact Sciences 16.26% Cancer and hereditary tests United States
9 Myriad Genetics 12.20% Hereditary cancer and prenatal tests United States
10 Revvity 8.13% Newborn screening and genetic testing United States

Note: Company shares are 2025 estimates.

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Natera led the DNA testing market with an estimated 24.39% share of 2025 revenue, followed by Labcorp at 24.39% share and Illumina at 24.39% share. Natera leads with panorama NIPT, Signatera and Horizon carrier tests, Labcorp competes with genetic and Invitae testing, and Illumina offers sequencing systems and assays. Quest Diagnostics, Thermo Fisher Scientific, BGI Genomics, Ancestry, Exact Sciences, Myriad Genetics and Revvity compete through clinical genetic testing, PCR, sequencing and forensic DNA kits, NIPT and genetic testing, ancestryDNA consumer tests, cancer and hereditary tests, hereditary cancer and prenatal tests and newborn screening and genetic testing. The top 10 companies accounted for an estimated 182.93% of 2025 revenue, while the remaining -82.93% was shared among many regional labs, forensic providers and consumer DNA brands. The DNA testing market is fragmented, and competition centres on test accuracy, menu breadth, turnaround time, reimbursement, data privacy, genetic counselling support and price.

Company Snapshots

Natera: Natera is headquartered in the United States. It held 24.39% of revenue in 2025. Its offering centres on Panorama NIPT, Signatera and Horizon carrier tests. Natera has been positioned as a Leader in the Towards Healthcare Companies Quadrant.

Labcorp: Labcorp, part of Laboratory Corporation of America Holdings, is headquartered in the United States. It held an 24.39% share of the DNA testing market in 2025. Its offering revolves around Genetic and Invitae testing. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.

Illumina: Illumina has its global headquarters in the United States. The company held a 24.39% share in 2025. Its offering centres on Sequencing systems and assays. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.

Quest Diagnostics: Quest Diagnostics is headquartered in the United States. It held an estimated 20.33% share of the DNA testing market in 2025. Its offering centres on Clinical genetic testing. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.

Thermo Fisher Scientific: Thermo Fisher Scientific has its corporate headquarters in the United States. It held an 20.33% share of the DNA testing market in 2025. Its offering centres on PCR, sequencing and forensic DNA kits. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.

BGI Genomics: BGI Genomics is headquartered in China. BGI Genomics held a 16.26% share in 2025. Its offering centres on NIPT and genetic testing. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.

Ancestry: Ancestry, part of Ancestry.com LLC, is headquartered in the United States. The company held 16.26% of the market in 2025. Its portfolio comprises AncestryDNA consumer tests. In the Towards Healthcare Companies Quadrant it is positioned as an Innovator.

Exact Sciences: Exact Sciences has its corporate headquarters in the United States. It held an 16.26% share in 2025. Its offering centres on Cancer and hereditary tests. In the Towards Healthcare Companies Quadrant it is positioned as an Innovator.

Myriad Genetics: Myriad Genetics is headquartered in the United States. The company held 12.20% of revenue in 2025. Its offerings centre on Hereditary cancer and prenatal tests. Myriad Genetics has been positioned as an Innovator in the Towards Healthcare Companies Quadrant.

Revvity: Revvity has its global headquarters in the United States. It held an 8.13% share in 2025. Its offering revolves around Newborn screening and genetic testing. In the Towards Healthcare Companies Quadrant it is positioned as an Innovator.

Companies Ecosystem

The DNA testing ecosystem links technology providers, testing labs, consumer companies, users and regulators, with each stage adding value before products reach end users.

Ecosystem Stage Role in the Market Key Companies
Technology Providers Supply sequencers and reagents Illumina, Thermo Fisher, BGI
Testing Labs Run tests Natera, Labcorp, Quest, Myriad
Consumer Companies Sell kits online Ancestry, 23andMe Research Institute
Users Order and use results Physicians, patients, consumers, forensic agencies
Regulators Set testing and privacy rules FDA, CLIA, GDPR, state privacy laws

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Technology Providers: Supply sequencers and reagents. Key participants include Illumina, Thermo Fisher, BGI.

Testing Labs: Run tests. Key participants include Natera, Labcorp, Quest, Myriad.

Consumer Companies: Sell kits online. Key participants include Ancestry, 23andMe Research Institute.

Users: Order and use results. Key participants include Physicians, patients, consumers, forensic agencies.

Regulators: Set testing and privacy rules. Key participants include FDA, CLIA, GDPR, state privacy laws.

Value in the DNA testing market flows from upstream material and technology suppliers to manufacturers and service providers, then through distribution partners to end users. Companies that integrate several stages or build long-term relationships with end users capture a larger share of this value.

Towards Healthcare Companies Quadrant

The Towards Healthcare Companies Quadrant positions key participants in the DNA testing market by market strength, reflecting revenue scale, market share and geographic reach, and by innovation and growth strategy, reflecting product portfolio breadth, R&D intensity and partnerships. Positions reflect each company's estimated 2025 share of the DNA testing market and our assessment of its product innovation, portfolio breadth and partnerships.

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Leaders: Natera, Labcorp, Illumina, Quest Diagnostics, Thermo Fisher Scientific and BGI Genomics combine high market share with broad portfolios and strong innovation.

Innovators: Ancestry, Exact Sciences, Myriad Genetics and Revvity bring newer technologies and specialised products.

Recent Developments

  • June 2026: 23andMe re-emerged from bankruptcy as the nonprofit 23andMe Research Institute, holding DNA data from about 13 million users, with its founder targeting 100 million users.

Market Segments

By Test Type

  • Clinical & Hereditary Disease Testing
  • Oncology Genetic Testing
  • Prenatal & Newborn Testing
  • Direct-to-Consumer Testing
  • Forensic & Paternity Testing

By Technology

  • Next-Generation Sequencing
  • PCR
  • Microarray
  • Others

By End User

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Forensic Laboratories
  • Consumers

By Region

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Spain, Rest of Europe)
  • Asia Pacific (China, Japan, India, South Korea, Taiwan, Rest of Asia Pacific)
  • Latin America (Brazil, Argentina, Rest of Latin America)
  • Middle East & Africa (GCC, South Africa, Rest of MEA)

Research Methodology

The market is defined as tests that analyze human DNA, including clinical diagnostic and hereditary disease testing, oncology genetic testing, prenatal and newborn testing, direct-to-consumer ancestry and health tests, forensic DNA testing, and paternity and relationship testing, using PCR, next-generation sequencing, microarray and other technologies, and offered by hospitals and clinics, diagnostic laboratories, forensic laboratories and consumer testing companies. The 2025 base year was built bottom-up from demand volumes and average prices by test type, technology and end user and region, and checked top-down against the market-specific revenues of leading companies and published estimates. Segment, regional and company values were allocated from test type, technology and end user and region demand. Key estimates were verified by cross-checking company disclosures, regulatory and industry data and published third-party estimates, and inputs that could not be reconciled were excluded. All segment, regional and company figures were reconciled to the same 2025 base year, and the 2026-2035 forecast, which applies a constant CAGR from the 2025 base, was recalculated and validated.

Analyst View: The market is set for steady expansion as falling sequencing costs and related demand keep growing. Our estimate links value to underlying demand, installed base and pricing, so the forecast follows real adoption rather than headline hype. The main upside comes from genomic newborn screening and pharmacogenomics, while the main risks are privacy concerns and reimbursement gaps.

References

Meet the Team

Payal Rabde

Payal Rabde

Principal Consultant

Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.

Learn more about Payal Rabde
Aditi Shivarkar

Aditi Shivarkar LinkedIn

Reviewed By

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar